FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011959390> ?p ?o ?g. }

• W3011959390 endingPage "e954" @default.
• W3011959390 startingPage "e946" @default.
• W3011959390 abstract "Abstract The safety and activity of immune checkpoint inhibitors have been characterized in interventional and observational studies. However, only small studies have specifically investigated these agents in patients who are excluded or underrepresented in clinical trials, frequently referred to as “special populations” or “underrepresented populations.” These include older adults, those with dysregulated immune activation, patients with a compromised immune function, and those carrying major viral infections, lymphoproliferative diseases, and major organ dysfunctions. Therefore, there remains substantial uncertainty regarding the use of immune checkpoint inhibitors in these specific settings. The Network of Italian Supportive Care in Oncology has carried out a multidisciplinary project, with the contribution of oncologists and other specialists, to retrieve the existing evidence on the use of immunotherapy in patients with solid and hematological cancers with the final aim to provide an expert guidance. The results of this effort are presented in this article, which is focused on patients with major viral infections or those with immune dysregulation/autoimmune diseases, and could be useful to guide decisions in clinical practice and to design prospective clinical trials focusing on the use of immunotherapy in these populations. Implications for Practice Substantial uncertainty remains regarding the use of immune checkpoint inhibitors in “underrepresented” patients, such as older adults, those with dysregulated immune activation, and patients with a compromised immune function, major viral infections, lymphoproliferative diseases or major organ dysfunctions. The Network of Italian Supportive Care in Oncology has carried out a multidisciplinary project to retrieve the existing evidence on the use of immunotherapy in underrepresented patients with cancer in order provide an expert guidance. The results of this effort, with a focus on patients with major viral infections or those with immune dysregulation/autoimmune diseases, are presented in this article and could be useful to guide decisions both in clinical practice and to design clinical trials." @default.
• W3011959390 created "2020-03-23" @default.
• W3011959390 creator A5007575010 @default.
• W3011959390 creator A5007965725 @default.
• W3011959390 creator A5009256008 @default.
• W3011959390 creator A5014074160 @default.
• W3011959390 creator A5016516607 @default.
• W3011959390 creator A5018624121 @default.
• W3011959390 creator A5018764793 @default.
• W3011959390 creator A5023893215 @default.
• W3011959390 creator A5031997195 @default.
• W3011959390 creator A5038918288 @default.
• W3011959390 creator A5058643588 @default.
• W3011959390 creator A5059391185 @default.
• W3011959390 creator A5061441951 @default.
• W3011959390 creator A5062110064 @default.
• W3011959390 creator A5066790760 @default.
• W3011959390 creator A5072668656 @default.
• W3011959390 creator A5076941172 @default.
• W3011959390 creator A5084906998 @default.
• W3011959390 creator A5086743232 @default.
• W3011959390 creator A5089288192 @default.
• W3011959390 date "2020-03-17" @default.
• W3011959390 modified "2023-10-06" @default.
• W3011959390 title "Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders" @default.
• W3011959390 cites W1896688767 @default.
• W3011959390 cites W2128965385 @default.
• W3011959390 cites W2193769500 @default.
• W3011959390 cites W2337569104 @default.
• W3011959390 cites W2512614851 @default.
• W3011959390 cites W2525217971 @default.
• W3011959390 cites W2531040620 @default.
• W3011959390 cites W2546700240 @default.
• W3011959390 cites W2547391316 @default.
• W3011959390 cites W2589016133 @default.
• W3011959390 cites W2592187743 @default.
• W3011959390 cites W2612457499 @default.
• W3011959390 cites W2621266854 @default.
• W3011959390 cites W2673218446 @default.
• W3011959390 cites W2735521483 @default.
• W3011959390 cites W2736166064 @default.
• W3011959390 cites W2749376811 @default.
• W3011959390 cites W2765472296 @default.
• W3011959390 cites W2765836977 @default.
• W3011959390 cites W2772134558 @default.
• W3011959390 cites W2774734531 @default.
• W3011959390 cites W2781601010 @default.
• W3011959390 cites W2783621911 @default.
• W3011959390 cites W2784120148 @default.
• W3011959390 cites W2789417379 @default.
• W3011959390 cites W2795698310 @default.
• W3011959390 cites W2800772239 @default.
• W3011959390 cites W2805592007 @default.
• W3011959390 cites W2810776198 @default.
• W3011959390 cites W2833678834 @default.
• W3011959390 cites W2866189919 @default.
• W3011959390 cites W2883959012 @default.
• W3011959390 cites W2884259031 @default.
• W3011959390 cites W2884859985 @default.
• W3011959390 cites W2887772216 @default.
• W3011959390 cites W2890934903 @default.
• W3011959390 cites W2897435840 @default.
• W3011959390 cites W2899970113 @default.
• W3011959390 cites W2900778493 @default.
• W3011959390 cites W2906910378 @default.
• W3011959390 cites W2908054647 @default.
• W3011959390 cites W2908431216 @default.
• W3011959390 cites W2911264428 @default.
• W3011959390 cites W2915650040 @default.
• W3011959390 cites W2916937155 @default.
• W3011959390 cites W2921256116 @default.
• W3011959390 cites W2936932417 @default.
• W3011959390 cites W2940759533 @default.
• W3011959390 cites W2942287621 @default.
• W3011959390 cites W2943935507 @default.
• W3011959390 cites W2946312326 @default.
• W3011959390 cites W2946800373 @default.
• W3011959390 cites W2946998144 @default.
• W3011959390 cites W2947960513 @default.
• W3011959390 cites W2948055829 @default.
• W3011959390 cites W2959224028 @default.
• W3011959390 cites W2962814122 @default.
• W3011959390 cites W2967913745 @default.
• W3011959390 cites W2974173963 @default.
• W3011959390 cites W2980687050 @default.
• W3011959390 doi "https://doi.org/10.1634/theoncologist.2020-0035" @default.
• W3011959390 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7288630" @default.
• W3011959390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32181960" @default.
• W3011959390 hasPublicationYear "2020" @default.
• W3011959390 type Work @default.
• W3011959390 sameAs 3011959390 @default.
• W3011959390 citedByCount "3" @default.
• W3011959390 countsByYear W30119593902021 @default.
• W3011959390 countsByYear W30119593902023 @default.
• W3011959390 crossrefType "journal-article" @default.
• W3011959390 hasAuthorship W3011959390A5007575010 @default.
• W3011959390 hasAuthorship W3011959390A5007965725 @default.
• W3011959390 hasAuthorship W3011959390A5009256008 @default.

• next